Connect with us
According to regulations, an accelerated authorization requires a confirmatory trial, so Pharma Mar announced in December 2021 the start of a confirmatory Phase III clinical trial,...
The six listed pharmaceutical companies close the first quarter of 2022 with a stock market value of $16.7 billion (€15.1 billion). The biggest decline was registered...
The performance of the pharmaceutical sector in the third quarter was worse than that of the Ibex35, the Spanish benchmark index, which fell by 0.3% in...
Grifols, which specializes in the production of plasma derivatives, achieved a profit of $317.2 million (€266.8 million) in the first half of 2021, which translates into...
This past year was not a good one for the Spanish pharmaceutical sector. According to a calculation, the six listed companies on the continuous market has...
Pharma Mar's investment in research and development (R&D) rose by 19.6% to $17.7 million (€14.7 million). Other operating expenses fell by 13% to $15.5 million (€12.9...
Sylentis is preparing for a new trial. The study has been approved by the FDA in 30 days and will be part of the marketing authorization...